Understanding Provider Barriers to Hydroxyurea Use for Pediatric Sickle Cell Disease
Oyeku S, Green N, Pashankar F, Giardina P, Mullen C, Driscoll C. Understanding Provider Barriers to Hydroxyurea Use for Pediatric Sickle Cell Disease. Blood 2010, 116: 255. DOI: 10.1182/blood.v116.21.255.255.Peer-Reviewed Original ResearchSickle cell diseaseYears of ageEfficacy of hydroxyureaHU useUse of hydroxyureaMajority of providersCell diseaseSickle cell genotypeProvider barriersClinical indicationsHematology providersNIH Consensus Development ConferencePediatric sickle cell diseaseLong-term side effectsNational evidence-based guidelinesProvider levelBroader clinical indicationsChronic pain useAcute chest syndromePhase III trialsPatients ages 1Dose of hydroxyureaEvidence-based guidelinesOff-label useConsensus Development Conference